Русский
Soluble suppression of tumorigenicity 2 (sST2) as a predictor of adverse outcomes of chronic heart failure
DOI: https://dx.doi.org/10.18565/therapy.2023.1.63-69
Kravchenko A.Ya., Budnevsky A.V., Chernik T.A., Tokmachev R.E.
N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia
Purpose of the study: to evaluate the possibilities of soluble tumorigenicity suppressor 2 (sST2) using as a predictor of an adverse outcomes of CHF.
Material and methods. The study included 120 stable CHF patients. There were 37,5% of men (n=45) and 62,5% of women (n=75). The mean age was 66,37±8,47 years. At the first stage of the study, complaints and anamnesis were collected. A physical examination, a complete blood count, a biochemical blood test, an enzyme immunoassay with the determination of NT-proBNP, sST2, hs-CRP and TSH and an echocardiography were also performed. At the second stage, which was organized after 12 months, data were collected on the clinical course and outcomes of CHF.
Results. The median level of sST2 in the study sample was 32,15 ng/ml [22,39; 38,59]. In the group of patients of I FC CHF this indicator was 24,72 ng/ml [17,9; 34,38], in II FC – 28,62 ng/ml [20,84; 36,24], in III FC – 37,11 ng/ml [31,2; 45,59], in FC IV – 37,74 ng/ml [32,14; 46,89]. An increase in the proportion of patients with an adverse outcomes was shown with an elevation in sST2 levels, which also corresponded to an increase in CHF FC.
Conclusion. The data obtained confirm the possibilities of sST2 in predicting the course of CHF. This may allow assessing the risks of an unfavorable course and the effectiveness of the applied treatment in this group of patients.
Literature
1. Groenewegen A., Rutten F.H., Mosterd A., Hoes A.W. Epidemiology of heart failure. Eur J Heart Fail. 2020; 22(8): 1342–56.https://dx.doi.org/10.1002/ejhf.1858. 2. Okumura N., Jhund P.S., Gong J. et al. Importance of clinical worsening of heart failure treated in the outpatient setting: Evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016; 133(23): 2254–62. https://dx.doi.org/10.1161/CIRCULATIONAHA.115.020729. 3. Терещенко С.Н., Галявич А.С., Ускач Т.М. с соавт. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11): 311–374. [Tereshchenko S.N., Galyavich A.S., Uskach T.M. et al. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 25(11): 311–374 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2020-4083. EDN: LJGGQV. 4. Cunningham J.W., Myhre P.L. NT-proBNP response to heart failure therapies: An imperfect surrogate. J Am Coll Cardiol. 2021; 78(13): 1333–36. https://dx.doi.org/10.1016/j.jacc.2021.07.045. 5. Кожевникова М.В., Беленков Ю.Н. Биомаркеры сердечной недостаточности: настоящее и будущее. Кардиология. 2021; 61(5): 4–16. [Kozhevnikova M.V., Belenkov Yu.N. Biomarkers in heart failure: Current and future. Kardiologiya = Cardiology. 2021; 61(5): 4–16 (In Russ.)]. https://dx.doi.org/10.18087/cardio.2021.5.n1530. EDN: NEGWWZ. 6. Tromp J., Westenbrink B.D., Ouwerkerk W. et al. Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2018; 72(10): 1081–90. https://dx.doi.org/10.1016/j.jacc.2018.06.050. 7. McCarthy C.P., Januzzi J.L. Jr. Soluble ST2 in heart failure. Heart Fail Clin. 2018; 14(1): 41–48.https://dx.doi.org/10.1016/j.hfc.2017.08.005. 8. Immanuel S., Mandey N.M., Makmun L.H. ST2 levels before and after treatment of NYHA III and IV heart failure. Acta Med Indones. 2015; 47(4): 304–10. 9. Myhre P.L., Claggett B.L., Shah A.M. et al. Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial. Eur J Heart Fail. 2022; 24(7): 1200–8. https://dx.doi.org/10.1002/ejhf.2541. 10. Januzzi J.L. Jr, Myhre P.L. The challenges of NT-proBNP testing in HFpEF: Shooting arrows in the wind. JACC Heart Fail. 2020; 8(5): 382–85. https://dx.doi.org/10.1016/j.jchf.2020.03.003. 11. Brunner-La Rocca H.P., Sanders-van Wijk S. Natriuretic peptides in chronic heart failure. Card Fail Rev. 2019; 5(1): 44–49.https://dx.doi.org/10.15420/cfr.2018.26.1. 12. Curinier C., Solecki K., Dupuy A.M. et al. Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial. Contemp Clin Trials. 2018; 66: 45–50.https://dx.doi.org/10.1016/j.cct.2018.01.007. 13. Aimo A., Januzzi J.L. Jr, Vergaro G. et al. Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. Eur J Heart Fail. 2020; 22(11): 2078–88.https://dx.doi.org/10.1002/ejhf.1701. 14. Demyanets S., Kaun C., Kaider A. et al. The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery. Cardiovasc Diabetol. 2020; 19(1): 26.https://dx.doi.org/10.1186/s12933-020-01001-y. 15. Aimo A., Januzzi J.L. Jr, Bayes-Genis A. et al. Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week. J Am Coll Cardiol. 2019; 74(17): 2193–203. https://dx.doi.org/10.1016/j.jacc.2019.08.1039.
About the Autors
Andrey Ya. Kravchenko, MD, professor of the Department of faculty therapy, N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia. Address: 394036, Voronezh, 10 Studencheskaya Str. E- mail: a.kravchenko@vrngmu.ru. ORCID: https://orcid.org/0000-0003-0297-1735
Andrey V. Budnevsky, MD, professor, head of the Department of faculty therapy, N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia. Address: 394036, Voronezh, 10 Studencheskaya Str. E- mail: avbudnevski@vrngmu.ru. ORCID: https://orcid.org/0000-0002-1171-2746
Tatiana A. Chernik, postgraduate student of the Department of faculty therapy, N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia. Address: 394036, Voronezh, 10 Studencheskaya Str. E- mail: ch01@mail.ru. ORCID: https://orcid.org/0000-0003-1371-0848
Roman E. Tokmachev, PhD of Medical Sciences, associate professor of the Department of faculty therapy,
N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia. Address: 394036, Voronezh, 10 Studencheskaya Str. E- mail: r.e.tokmachev@vrngmu.ru. ORCID: https://orcid.org/0000-0001-6379-4635
Similar Articles
